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ABSTRACT
We describe AHA utilization pattern according to age and renal function in type 
2 diabetes mellitus (T2DM), in real-life conditions.
The analysis was performed using the data set of electronic medical records collected 
between 1 January and 31 December, 2011 in 207 Italian diabetes centers. The study 
population consisted of 157,595 individuals with T2DM. The AHA treatment regimens 
was evaluated. Kidney function was assessed by eGFR, estimated using the CKD-EPI 
formula. Other determinations: HbA1c, blood pressure (BP), low- density lipoprotein 
(LDL-c), total and high density lipoprotein cholesterol (TC and HDL-c), triglycerides (TG) 
and serum uric acid (SUA). Quality of care was assessed through Q score.
The proportion of subjects taking metformin declined progressively across age 
quartiles along with eGFR values, but remained high in oldest subjects (i.e. 54.5 
%). On the other hand, the proportion of patients on secretagogues or insulin 
increased with aging (i.e. 54.7% and 37% in the fourth age quartile, respectively). 
The percentage of patients with low eGFR (i.e. <30 ml/min/1.73m2) taking either 
metformin or sulphonilureas/repaglinide was particularly high (i.e. 15.3% and 34.3% 
respectively).
In a large real-life cohort of T2DM, metformin or sulphonylureas/repaglinide, 
although not recommended, are frequently prescribed to elderly subjects with severe 
kidney disease.
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INTRODUCTION
Diabetes has been estimated to account for 
approximately 1.5 million deaths in 2012, with more than 
80% of diabetes-related deaths in low- and middle-income 
countries [1]. Lifestyle modification and glucose-lowering 
drug treatment are the mainstay of therapy to prevent and 
delay diabetes-related complications [2–3].
Even though a large number of antihyperglycemic 
agents are approved for type 2 diabetes (T2DM), major 
T2DM treatment guidelines suggest metformin as first-line 
drug treatment, and, if glycemic control is not achieved, 
the addition of a second drug is recommended [2–3].
Accordingly, in real-life conditions the majority 
of people with T2DM take metformin alone or in 
combination, although prescription is not always 
appropriate with regards to age and renal function 
limitations [4–6]. In fact, while the cardiovascular benefits 
associated to the use of metformin have been described, a 
careful assessment of kidney function is necessary prior 
to prescribe this drug as it is primarily eliminated via the 
kidney [7]. More recently, limitations on the use of this 
drug in individuals with mild or moderate impairment 
of renal function have been disputed [8–10], because 
of poor evidence on a specific safety threshold and the 
lack of clear-cut evidence supporting increased risk of 
complications (especially lactic acidosis) in the presence 
of mild or moderate renal impairment. Nonetheless, it 
is agreed upon that this drug should not be used in the 
presence of severe kidney dysfunction, i.e. GFR below 30 
ml/min/1.73m2 [2–3].
Age also needs to be taken into account when 
choosing antihyperglycemic agents in the clinical 
setting. This is mainly due to a well known reduction 
in GFR with aging which may foster the risk of severe 
hypoglycemic events [11]. To date, only few large studies 
have investigated the impact of age and impaired kidney 
function on the use of antihyperglycemic drugs, mainly 
metformin, in real-life clinical conditions [10, 12–13].
In this context, the large database of the AMD 
Annals initiative [14] provides a unique opportunity to 
analyse prescription patterns in Italy and correlate them 
with the quality of care, assessed through a validated score 
(Q score).
Therefore, aim of this report was to assess 
antihyperglycemic treatment, mainly focused on metformin 
use, in a large sample of patients with T2DM, according to 
age and kidney function in real-life conditions.
RESULTS
Clinical features of the whole study sample 
are reported in Table 1. Overall, the mean age of the 
participating patients was 68±11 years, 56.7% patients 
were males and the mean duration of diabetes was 11±9 
years. Mean BMI was 30±5 Kg/m2. Glycemic control, as 
well as, lipid parameters and BP levels were fairly good, 
being mean HbA1c, LDL-c and BP values 7.2± 1.3%, 
101±33 mg/dL and 137±18/7±89 mmHg, respectively. 
Mean eGFR was 76±21 mL/min/1.73m2. In Table 1 
we describe also participants’ clinical characteristics 
according to age quartiles. Older participants had longer 
duration of diabetes; lower BMI, waist circumference and 
triglyceride levels, as well as, higher HDL-c. Systolic BP 
and antihypertensive treatment rate increased with age, 
while the percentage of current smokers decreased. It is 
worth noting that mean HbA1c was 7.1% in patients in the 
fourth quartile (mean age 81 years), thus indicating that 
almost half of patients within this class had HbA1c values 
below 7.0% and therefore were, very likely, overtreated.
As expected, serum creatinine increased and eGFR 
declined progressively as a function of age. Prevalence 
of patients with eGFR <60 ml/min/1.73m2 increased 
across age quartiles form 4.8% in the first to 45.3% in 
the forth quartile. The proportion of both micro- and 
macroalbuminuria also significantly increased with age 
(Table 1).
Antihyperglycemic drugs utilization rate in the 
whole population and across the age quartiles is also 
reported in Table 1. Patients taking metformin decreased 
with age, being 77.1% in the lowest quartile and 54.5% 
in the highest quartile. Use of pioglitazone (the only 
thiazolidinedione available in Italy) also decreased across 
age quartiles and eGFR classes, while treatment with 
sulphonilureas/repaglinide or insulin increased from the 
lowest to the highest quartile.
The quality of care, as indicated by Q score, was 
similar across age quartiles (Supplementary Figure 1).
In Table 2 the clinical features of our population 
are described as stratified according to eGFR classes. 
Age, duration of diabetes, triglyceride levels, presence 
of retinopathy, prevalence rates of micro- and 
macroalbuminuria, as well as, of antihypertensive, lipid-
lowering and antiplatelet treatments increased along with 
eGFR decrease. However, although metformin utilization 
decreased in parallel with eGFR values, it is worth to 
underline that 617 (15.3%) patients with eGFR below 
30 ml/min/1.73m2 were kept on metformin (alone or in 
combination with other oral hypoglycaemic agents or 
insulin). Similarly sulphonilureas/repaglinide utilization 
also decreased in patents with low eGFR but a large 
percentage of patients with eGFR <30 ml/min/1.73m2 
was still taking sulphonilureas/repaglinide. Finally, 
insulin utilization rate increased with decreased eGFR as 
expected, and in fact 68.4% of patients with eGFR <30 ml/
min/1.73m2 was on insulin treatment.
The quality of care, as indicated by Q score, was 
similar across eGFR classes (Supplementary Figure 1).
When grouping the whole sample according to 
antihyperglycemic treatment (Supplementary Table 1), 
patients on insulin (alone or in combination with metformin) 
turned out to be older and had a longer duration of 
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Table 1: Clinical Characteristics of the whole sample and divided according to age quartiles
All <62 years 62-69 years 70-75 years >75 years p
n=157595 n=39407 n=39394 n=39404 n=39390




23345 (59.3%) 22140 (56.2%) 19131 (48.6%) <0.001
Age (years) 68±11 53±7 65±2 72±2 81±4 -




7355 (32.3%) 6741 (31.4%) 5572 (28.0%) <0.001




4238 (18.6%) 2617 (12.2%) 1333 (6.7%) <0.001
Age at DM diagnosis (years) 56±12 45±9 54±8 59±9 65±11 <0.001
Known duration of diabetes 
(years)
11±9 8±7 10±8 13±9 15±11 <0.001
HbA1c (%) 7.2±1.3 7.3±1.5 7.2±1.3 7.2±1.2 7.2±1.2 <0.001
BMI (Kg/m2) 30±5 30±6 30±5 29±5 28±5 <0.001
BMI Men (Kg/m2) 29±5 30±5 30±5 29±4 28±4 <0.001
BMI Women (Kg/m2) 30±6 31±7 31±6 30±6 29±5 <0.001
Waist circumference (cm) 104±13 104±14 104±13 103±12 102±12 <0.001
Waist circumference Men (cm) 104±12 105±13 105±12 104±12 104±11 <0.001
Waist circumference Women 
(cm)
102±13 103±15 103±13 102±13 101±12 <0.001
Triglycerides (mg/dL) 137±90 151±118 137±82 132±84 128±69 <0.001
HDL (mg/dL) 50±14 48±14 50±14 51±14 52±15 <0.001
HDL Men (mg/dL) 47±13 45±13 47±13 48±13 48±14 <0.001
HDL Women (mg/dL) 54±15 53±15 54±14 54±15 55±15 <0.001
LDL (mg/dL) 101±33 106±34 100±33 99±32 100±33 <0.001
Non-HDL (mg/dL) 128±37 135±40 127±37 124±36 125±36 <0.001
Systolic BP (mmHg) 137±18 132±17 137±18 139±19 140±19 <0.001
Diastolic BP (mmHg) 78±9 80±10 78±9 77±9 76±9 <0.001
Pulse pressure (mmHg) 59±16 53±14 59±15 62±16 64±17 <0.001




10645 (27.0%) 11535 (29.3%) 13364 (33.9%) <0.001




8392 (21.3%) 8995 (22.8%) 10425 (26.5%) <0.001
Macroalbuminuria (n) 9586 (6.1%) 1854 (4.7%) 2253 (5.7%) 2540 (6.4%) 2939 (7.5%) <0.001
Serum creatinine (mg/dL) 0.98±0.54 0.86±0.41 0.93±0.50 1.01±0.55 1.10±0.63 <0.001
eGFR (mL/min/1.73 m2) 76±21 93±17 80±17 72±18 61±19 <0.001




5729 (14.5%) 6259 (15.9%) 5948 (15.1%) <0.001
Antihyperglycemic treatments - 
Lifestyle (n)
8229 (5.2%) 2114 (5.4%) 2145 (5.4%) 2150 (5.5%) 1820 (4.6%) <0.001
(Continued )
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disease, a lower eGFR and a higher prevalence of micro-
macroalbuminuria as compared to those taking either 
metformin alone or other antihyperglycemic agents.
Then we analysed the distribution of antihyperglycemic 
agents according to both age and eGFR categories it 
appeared evident, although unexpected, that metformin 
All <62 years 62-69 years 70-75 years >75 years p
n=157595 n=39407 n=39394 n=39404 n=39390




28342 (71.9%) 30543 (77.5%) 31751 (80.6%) <0.001




24518 (62.2%) 26103 (66.2%) 26260 (66.7%) <0.001




24362 (61.8%) 24674 (62.6%) 21788 (55.3%) <0.001




22392 (56.8%) 22947 (58.2%) 20539 (52.1%) <0.001




8872 (22.5%) 10253 (26.0%) 10645 (27.0%) <0.001
eGFR<60 mL/min/1.73 m2 (n) 35166 
(22.3%)
1879 (4.8%) 5335 (13.5%) 10113 (25.7%) 17839 (45.3%) <0.001




19292 (49.7%) 19675 (50.6%) 20775 (53.5%) <0.001
Total cholesterol (mg/dL) 177±39 182±40 176±38 175±37 176±38 <0.001




11713 (31.5%) 10610 (28.8%) 9614 (26.7%) <0.001




13057 (35.7%) 12076 (33.4%) 12178 (34.4%) <0.001




16990 (46.7%) 16209 (44.8%) 16381 (46.4%) <0.001






18069 (53.5%) 19204 (57.1%) 18637 (58.0%) <0.001
Treatment with fibrates (n) 4588 (2.9%) 1652 (4.2%) 1210 (3.1%) 1011 (2.6%) 715 (1.8%) <0.001




29574 (75.1%) 26798 (68.0%) 21473 (54.5%) <0.001




18871 (47.9%) 19996 (50.7%) 21552 (54.7%) <0.001
Acarbose (n) 4613 (2.9%) 937 (2.4%) 1099 (2.8%) 1233 (3.1%) 1344 (3.4%) <0.001
Glitazones (n) 4280 (2.7%) 1250 (3.2%) 1263 (3.2%) 1090 (2.8%) 677 (1.7%) <0.001




11017 (28.0%) 12489 (31.7%) 14571 (37.0%) <0.001
Mean±SD or absolute frequency (percentage). ACE-Is=angiotensin converting enzyme-inhibitors, ARBs=angiotensin 
II receptor antagonists, BMI=body mass index, BP=blood pressure, eGFR=estimated glomerular filtration rate, 
HbA1c=glycated hemoglobin, HDL =high-density lipoprotein cholesterol, LDL =low-density lipoprotein cholesterol. 
Patients’ missing data: age at diagnosis and duration of diabetes in 8435 (5.4%), BMI in 14918 (9.5%), Waist circumference 
in 111567 (70.8%), HbA1c in 2291 (1.5%), total cholesterol in 8127 (5.2%), triglycerides in 10293 (6.5%), HDL-c in 12812 
(8.1%), LDL-c in 13495 (8.6%), Non-HDL in 13799 (8.8%), serum uric acid in 81772 (51.9%), GGT in 75760 (48.1%), 
AST/GOT in 47264 (30%), ALT/GPT in 42967 (27.3%), blood pressure in 24106 (15.3%), and smoking status in 69213 
(43.9%). The p values refer to significance of mixed regression models (linear for continuous and logistic for categorical 
variables) with age quartiles as dependent variables.
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Table 2: Clinical Characteristics of the whole sample and divided according to classes of estimated Glomerular 
Filtration Rate
GFR>90 GFR 60-90 GFR 30-60 GFR<30 Overall
n=47254 n=75175 n=31137 n=4029 p
Male sex (n) 28595 (60.5%) 43080 (57.3%) 15712 (50.5%) 1903 (47.2%) <0.001
Age (years) 59±10 70±9 75±8 76±9 <0.001
Former smokers (n) 7612 (26.9%) 12657 (30.5%) 4975 (30.3%) 631 (29.9%) <0.001
Current smokers (n) 7083 (25.0%) 5858 (14.1%) 1658 (10.1%) 194 (9.2%) <0.001
Age at DM diagnosis (years) 50±11 58±11 60±12 59±13 <0.001
Known duration of diabetes 
(years)
9±8 12±9 14±10 17±11 <0.001
HbA1c (%) 7.3±1.4 7.2±1.3 7.3±1.3 7.3±1.3 <0.001
BMI (Kg/m2) 30±6 29±5 30±5 30±5 <0.001
BMI Men (Kg/m2) 29±5 29±5 29±5 29±5 <0.001
BMI Women (Kg/m2) 31±6 30±6 30±6 31±6 <0.001
Waist circumference (cm) 103±13 103±12 105±12 107±13 <0.001
Waist circumference Men 
(cm)
104±13 104±12 106±12 108±13 <0.001
Waist circumference Women 
(cm)
102±14 102±13 104±13 105±13 <0.001
Triglycerides (mg/dL) 135±97 132±84 149±94 163±96 <0.001
HDL (mg/dL) 50±14 51±14 49±14 46±15 <0.001
HDL Men (mg/dL) 47±13 48±13 45±13 42±13 <0.001
HDL Women (mg/dL) 54±15 55±15 52±15 49±16 <0.001
LDL (mg/dL) 103±33 101±33 99±34 98±34 <0.001
Non-HDL (mg/dL) 129±38 126±37 128±38 130±41 <0.001
Systolic BP (mmHg) 134±18 138±18 139±19 139±20 <0.001
Diastolic BP (mmHg) 79±9 78±9 77±10 75±10 <0.001
Pulse pressure (mmHg) 56±15 60±16 62±17 63±18 <0.001
Albuminuria (n) 11246 (23.8%) 19681 (26.2%) 12026 (38.6%) 2434 (60.4%) <0.001
Microalbuminuria (n) 9493 (20.1%) 16038 (21.3%) 8877 (28.5%) 1393 (34.6%) <0.001
Macroalbuminuria (n) 1753 (3.7%) 3643 (4.8%) 3149 (10.1%) 1041 (25.8%) <0.001
Serum creatinine (mg/dL) 0.72±0.13 0.91±0.15 1.30±0.25 2.93±2.17 -
eGFR (mL/min/1.73 m2) 99±8 77±9 48±8 22±7 -
Retinopathy (n) 5281 (11.2%) 10168 (13.5%) 5759 (18.5%) 1042 (25.9%) <0.001
Antihyperglycemic 
treatments - Lifestyle (n)
2424 (5.1%) 4414 (5.9%) 1280 (4.1%) 111 (2.8%) <0.001
Antihypertensive treatment 
(n)
27506 (58.2%) 54777 (72.9%) 26553 (85.3%) 3588 (89.1%) <0.001
Treatment with ACE-Is/
ARBs (n)
23520 (49.8%) 46837 (62.3%) 22714 (72.9%) 2750 (68.3%) <0.001
(Continued )
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and sulphonilureas/repaglinide were largely used in elderly 
patients in spite of very low eGFR (i.e. eGFR <30 ml/
min/173m2) (Supplementary Table 2 and Figure 1).
DISCUSSION
In this report, we assessed prescription patterns of 
AHA, mainly focused on metformin, according to age and 
kidney function in a large sample of patients with T2DM 
attending diabetes centers in Italy, in real-life conditions.
T2DM is a major health problem for the aging 
population and, therefore, older people (i.e. > 65 years) are 
highly prevalent among those attending diabetes centers, 
being in our series more than 50%. Age should be taken 
into account when choosing the most appropriate AHA, by 
keeping an eye not only on target HbA1c [2–3, 15], which 
often requires to be slightly higher than usual, but also, on 
progressive GFR decline occurring in people aged 65+.
It’s worth emphasizing that about half of patients 
in the highest age quartile (i.e. median age: 80 years) had 
HbA1c levels below 7.0%. Thus, although a less stringent 
glycemic control is usually suggested in these patients 
[15], our findings could suggest the presence of a possibly 
overtreatment in real-life conditions.
A little proportion of our patients was on 
pioglitazone treatment. Given the well know side effects 
(i.e. fluid retention, heart failure, fractures), although not 
contraindicated, its use decreased in elderly and among 
patients with low or very low eGFR.
As expected, elderly persons had a lower eGFR. In 
this subgroup of patients, a large proportion (i.e. more than 
50%) was treated with sulphonilureas/repaglinide and thus 
exposed to an increased risk of hypoglycemic events. In 
fact, a recent survey, investigating in a real-life condition 
the risk of severe hypoglycemia in 29,485 sulphonilurea 
treated diabetic patients shown as it was related to older 
age and decreased eGFR [16]. Older age and diabetic 
complication, together with diminished food intake, 
alcohol abuse, use of other medication and concomitant 
infection, were also the main causes of hospital admission-
required hypoglycemia in an observational study including 
16,865 T2DM patients from Capital Region of Denmark 
taking sulphonilureas [17].
Mainly based on data from the UKPDS sub-
study related to overweight patients [18], nowadays 
international treatment guidelines recommend metformin 
as first-line AHA in patients with T2DM [2–3]. Despite 
no firm consensus on that, several observational studies 
GFR>90 GFR 60-90 GFR 30-60 GFR<30 Overall
n=47254 n=75175 n=31137 n=4029 p
Lipid-lowering treatment (n) 24760 (52.4%) 44003 (58.5%) 19287 (61.9%) 2640 (65.5%) <0.001
Treatment with statins (n) 22797 (48.2%) 40737 (54.2%) 17447 (56.0%) 2361 (58.6%) <0.001
Aspirin (n) 7679 (16.3%) 17615 (23.4%) 8788 (28.2%) 1202 (29.8%) <0.001
eGFR<60 mL/min/1.73 m2 0 (0.0%) 0 (0.0%) 31137 (100.0%) 4029 (100.0%) -
HbA1c ≥7% 23573 (50.6%) 37212 (50.2%) 16963 (55.3%) 2141 (54.1%) <0.001
Total cholesterol (mg/dL) 179±39 177±38 176±39 176±43 <0.001
Triglycerides ≥150 mg/dl (n) 12929 (29.0%) 20049 (28.4%) 10869 (38.0%) 1620 (45.2%) <0.001
HDL <40M <50F mg/dL (n) 15516 (35.2%) 22818 (33.0%) 11907 (42.5%) 1867 (53.5%) <0.001
LDL ≥100 mg/dL (n) 22213 (51.0%) 32993 (47.7%) 12568 (45.1%) 1521 (43.8%) <0.001
Blood Pressure ≥140/85 
mmHg (n)
20000 (48.7%) 35448 (55.5%) 14283 (56.3%) 1731 (54.8%) <0.001
Treatment with fibrates (n) 1170 (2.5%) 2049 (2.7%) 1218 (3.9%) 151 (3.7%) <0.001
Metformin (n) 37429 (79.2%) 54434 (72.4%) 15754 (50.6%) 617 (15.3%) <0.001
Sulphonylureas/Repaglinide 
(n)
21684 (45.9%) 38060 (50.6%) 15742 (50.6%) 1383 (34.3%) <0.001
Acarbose (n) 1267 (2.7%) 2096 (2.8%) 1120 (3.6%) 130 (3.2%) <0.001
Glitazones (n) 1437 (3.0%) 2056 (2.7%) 725 (2.3%) 62 (1.5%) <0.001
Insulin (n) 12007 (25.4%) 20693 (27.5%) 13375 (43.0%) 2756 (68.4%) <0.001
Mean±SD or absolute frequency (percentage). Overall p value refers to the significance of model with eGFR in the four 
categories as explanatory variable. Adjusted p value refers to significance of regression coefficient of each variable in a 
mixed linear model with continuous eGFR as dependent variable. Legend as in Table 1.
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support the concept that metformin is effective, as well as, 
devoid of any increased risk of acidosis, also in patients 
with significant degree of renal impairment (i.e. eGFR 
between 60 and 30 ml/min/1.73m2) [19–22]. In fact, an 
observational study on 51,675 Swedish people with T2DM 
found no increased risk of acidosis in metformin users 
with eGFR of 30-45 ml/min/1.73m2 compared with non-
users [10]. More recently, a systematic review by Crowley 
et al. [9] further confirmed metformin to be associated 
with improvements in clinical outcomes in patients with 
moderate CKD, thus supporting the recent changes in 
metformin labeling.
Consequently, to prevent patients from missing 
beneficial effects of metformin, some health agencies, 
including the National Institute for Health and Clinical 
Excellence [2–3], suggest initiation of that drug also 
in individuals with GFR 46 to <60 ml/min/1.73m2 and 
continuation with additional caution and dose reduction 
whenever GFR declines to 30-45 ml/min/1.73m2.
This position was also confirmed by Inzucchi et al. 
in a recent systematic review of 65 studies investigating 
upon the risk of lactic acidosis associated to metformin 
use. They concluded for a less strict approach to 
metformin treatment might be chosen, although with 
caution, in patients with T2DM and mild or moderate 
chronic kidney disease entangling lower doses and careful 
follow-up of kidney function [8]. These Authors also 
strongly suggested to refrain from using metformin in 
patients with GFR below 30 ml/min to avoid the risk of 
both lactic acidosis and of increased mortality previously 
shown to be associated with metformin use in patients 
having serum creatinine concentrations greater than 530 
μmol/L [12].
Although the use of metformin in our sample 
declined with age, the frequent inappropriate use of this 
drug in the elderly clearly stands out from our data. In 
fact, 13.4% (n=309) of the oldest patients with eGFR 
below 30 ml/min/1.73m2 were on metformin (alone or in 
combination with insulin), and thus at high risk for major 
complications.
Epidemiological data show suboptimal adherence 
to different guidelines, which have recommended various 
kidney function thresholds for metformin restriction in 
CKD. Our results are in keeping with data from Huang 
et al. who retrospectively reviewed metformin-treated 
patients with T2DM admitted to major teaching Hospitals 
in Australia. They reported that about 31% of these 
patients received the drug inappropriately, given the 
presence of contraindications. Kidney failure (i.e. GFR 
below 30 ml/min/1.73m2) was one of the most frequent 
contraindication [21]. In a study of 83,850 US veterans 
≥ 65 years of age with creatinine clearance ranging 
15–49 ml/min, metformin was among the 3 medications 
altogether accounting for 76% of renally misprescribed 
medications among patients with 30–49 ml/min creatinine 
clearance rate [22] and, according to the previously quoted 
systematic review [8], among patients with kidney-
related contraindication, as many as one-third were still 
prescribed metformin.
The awareness of risks associated with metformin 
misuse is increasing. In fact, a recent survey by Koro 
C et al. analyzing oral antidiabetic drug utilization 
Figure 1: Proportion of T2DM patients taking metformin according to age quartiles and eGFR classes.
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rates by 1,462 patients with T2DM and chronic 
kidney disease from the US NANHES IV database, 
found that 43.4% was taking OADs (24.0% were on 
sulphonilureas) but no patient with stage 4 and 5 CKD 
was taking metformin [13].
The reason why the inappropriate use of metformin 
is quite diffuse is beyond the aim of this survey. However, 
the evidence that not all physicians follow clinical practice 
guidelines [23] and that therapeutic inertia is still an issue 
[24] could account, at least in part, for metformin misuse. 
Furthermore, the barriers to start insulin therapy especially 
in elderly may have also contributed [25]. In addition, the 
fact that quality of care delivered to the patients did not 
differ according to age or eGFR classes allows us to rule 
out any clinical approach inequalities.
Our study has some limitations as well as several 
strengths. Among the former, we need to say that the 
data were collected in the 2011, when the use of new 
innovative antihyperglycemic agents such as DPP-4 
inhibitors, GLP-1 agonist or Glifozin was still trivial. In 
this regard. it is anyway worth to underline that these new 
classes of drugs are still underused in Italy [26]. Second, 
we have no information on metformin dosage and duration 
of treatment. On the other hand, we should mention the 
large size of the study cohort and the homogeneous 
geographical distribution of the recruiting centers, which 
certainly contribute to make the study population a good 
representation of real-life clinical practice. Furthermore, 
as some drugs sharing similar pharmacologic mechanisms 
(i.e. Sulphonylureas and Repaglinide) were pooled 
together in our database, we were unable to carry out 
separate analyses for each individual drug class.
In conclusion, although recent guidelines have 
taken a less stringent stance about contraindications 
to metformin treatment, clinical risk associated to the 
use of this drug remains high and should be avoided in 
the presence of severe CKD. Herewith reported and 
discussed data indicating the persistence of a significant 
degree of inappropriateness in the prescription of this 
drug, call to action for implementing more suitable use of 
antihyperglycemic drugs, especially in older patients with 
kidney dysfunction.
METHODS
Study setting, study patients and data sources
In the present report we analyzed a large cohort of 
patients with T2DM followed-up at 207 diabetes centers 
in Italy among those affiliated to the Italian Association 
of Clinical Diabetologists initiative aiming to investigate 
the use of antihyperglycemic treatment, according to 
age and kidney function. The centers participated in the 
study are homogeneously distributed throughout the 
country. The analysis was performed using the data set 
of electronic medical records collected between 1 January 
and 31 December 2011. For the purpose of the analysis, 
we considered only patients who were ≥18 years old and 
with data about estimated GFR (eGFR) and albuminuria. 
The study population consisted of 157,595 individuals 
with T2DM.
Data collection
Data from all participating centers were collected 
and centrally analyzed anonymously. The results were 
internally approved by the AMD Annals scientific 
committee. The diagnosis of T2DM was made at 
participating Diabetes Centers according to the American 
Diabetes Association 2003 criteria. This initiative includes 
measuring and monitoring HbA1c, blood pressure, low- 
density lipoprotein, total and high density lipoprotein 
cholesterol, triglycerides and serum uric acid by high 
standard auto-analyzers in public laboratories successfully 
participating in nationwide quality control programs. The 
use of specific classes of drugs (metformin, other AHA, 
statins and anti-hypertensive agents) was also evaluated. 
Kidney function was assessed by serum creatinine and 
urinary albumin excretion measurements. GFR was 
estimated for each patient using a standardized serum 
creatinine assay and the CKD-EPI formula [27]. To be 
included in the study, the patients had to have at least 
one measurement of serum creatinine, with concordant 
eGFR values, in the 3 months prior to study entry. 
Increased urinary albumin excretion was diagnosed as: i) 
microalbuminuria if urinary albumin concentration was 
>30 and ≤300 mg/l, or if UAE rate was >20 and ≤200 
μg/min, or if urinary albumin-to-creatinine ratio (ACR) 
was >2.5 mg/mmol in men and >3.5 mg/mmol in women 
and ≤30 mg/mmol in both genders; ii) macroalbuminuria 
if urinary albumin concentration was >300 mg/l, or if 
UAE rate was >200 μg/min, or if ACR was >30 mg/mmol 
in both genders. Albuminuria indicated patients with 
either micro- or macroalbuminuria. At each participating 
center, all patients underwent physical examination and 
BP measurements according to a standardized protocol. 
Information on the presence of diabetic retinopathy was 
also available.
Quality of care was assessed through the Q score, 
which was developed as part of the study QuED and 
subsequently validated in the study QUASAR [28].
Statistical analysis
Data are given as mean values ± standard deviation 
(SD); categorical variables are described as frequencies 
and percentages. Mixed regression models, with diabetes 
clinics fitted as random effect to consider possible 
differences in data across centres, were used to compare 
patients’ characteristics by groups. Continuous and 
categorical variables were analyzed, respectively, by linear 
and logistic mixed regression models. P values of <0.05 
Oncotarget9www.impactjournals.com/oncotarget
were considered statistically significant. The analyses 
were made using STATA software, Version 14 (StataCorp, 
College Station, Texas).
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